JNJ
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.
Johnson & Johnson (JNJ) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Revisions (D+). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-16 | C+ (2.6) | D+ (1.6) | B+ (3.8) | B (3.5) | D+ (1.6) | C+ (2.6) |
| 2026-11-09 | C+ (2.6) | D+ (1.6) | B+ (3.8) | B (3.5) | D+ (1.6) | C+ (2.6) |
| 2026-11-07 | C+ (2.6) | D+ (1.6) | B+ (3.8) | B (3.4) | D+ (1.6) | C+ (2.6) |
| 2026-11-06 | C+ (2.6) | D+ (1.6) | B+ (3.8) | B (3.4) | D+ (1.6) | C+ (2.6) |
| 2026-11-03 | C+ (2.6) | D+ (1.6) | B+ (3.8) | B (3.4) | D+ (1.6) | C+ (2.6) |